The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma

0570994 - ÚOCHB 2024 RIV NL eng J - Článek v odborném periodiku
Frejlachová, A. - Lencová, R. - Venhauerová, A. - Skaličková, M. - Uher, O. - Caisova, V. - Majer, Pavel - Tenora, Lukáš - Hansen, P. - Chmelař, J. - Kopecký, J. - Zhuang, Z. - Pacak, K. - Ženka, J.
The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma.
International Immunopharmacology. Roč. 118, May (2023), č. článku 110150. ISSN 1567-5769. E-ISSN 1878-1705
Institucionální podpora: RVO:61388963
Klíčová slova: cancer * pancreatic adenocarcinoma * intratumoral * immunotherapy * glutamine antagonist
Obor OECD: Medicinal chemistry
Impakt faktor: 5.6, rok: 2022
Způsob publikování: Omezený přístup
https://doi.org/10.1016/j.intimp.2023.110150

Despite constant advances in cancer research, the treatment of pancreatic adenocarcinoma remains extremely challenging. The intratumoral immunotherapy approach that was developed by our research group and was based on a combination of mannan-BAM, TLR ligands, and anti-CD40 antibody (MBTA) showed promising therapeutic effects in various murine tumor models, including a pancreatic adenocarcinoma model (Panc02). However, the efficacy of MBTA therapy in the Panc02 model was negatively correlated with tumor size at the time of therapy initiation. Here, we aimed to further improve the outcome of MBTA therapy in the Panc02 model using the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON). The combination of intratumoral MBTA therapy and intraperitoneal administration of DON resulted in the complete elimination of advanced Panc02 subcutaneous tumors (140.8 ± 46.8 mm3) in 50% of treated animals and was followed by development of long-term immune memory. In the bilateral Panc02 subcutaneous tumor model, we observed a significant reduction in tumor growth in both tumors as well as prolonged survival of treated animals. The appropriate timing and method of administration of DON were also addressed to maximize its therapeutic effects and minimize its side effects. In summary, our findings demonstrate that the intraperitoneal application of DON significantly improves the efficacy of intratumoral MBTA therapy in both advanced and bilateral Panc02 subcutaneous tumor murine models.
Trvalý link: https://hdl.handle.net/11104/0342323